Literature DB >> 10085500

The use of lofexidine by drug dependency units in the United Kingdom.

J S Akhurst1.   

Abstract

Data were collected on 1,074 opiate detoxifications conducted with lofexidine, from 40 drug dependency units in the United Kingdom. 671 patients (62.5%) attempted a detoxification in the community, with the remainder attempting an inpatient detoxification. Patients completing the detoxification started on a mean dose of 0.8 mg/day (median 0.6 mg/day), titrating to a mean dose of 2.2 mg/day (median 1.6 mg/day) and detoxifying in a mean of 10 days (median 10 days). Overall 614 patients (60.4%) successfully completed the detoxification. The most frequently recorded adverse events were dry mouth (5.3%), dizziness (8.5%) and sedation (6.6%). In conclusion, lofexidine is widely and successfully used to rapidly detoxify patients from a range of opiates.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10085500     DOI: 10.1159/000018962

Source DB:  PubMed          Journal:  Eur Addict Res        ISSN: 1022-6877            Impact factor:   3.015


  4 in total

1.  Evidence-based addiction medicine: the use of lofexidine for opioid detoxification.

Authors:  Babatunde Adetunji; Maju Mathews; Adedapo Williams; Olusanya Rufai
Journal:  Psychiatry (Edgmont)       Date:  2004-11

2.  Electrocardiographic effects of lofexidine and methadone coadministration: secondary findings from a safety study.

Authors:  John Schmittner; Jennifer R Schroeder; David H Epstein; Mori J Krantz; Nicole C Eid; Kenzie L Preston
Journal:  Pharmacotherapy       Date:  2009-05       Impact factor: 4.705

3.  A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.

Authors:  Elmer Yu; Karen Miotto; Evaristo Akerele; Ann Montgomery; Ahmed Elkashef; Robert Walsh; Ivan Montoya; Marian W Fischman; Joseph Collins; Frances McSherry; Kathy Boardman; David K Davies; Charles P O'Brien; Walter Ling; Herbert Kleber; Barbara H Herman
Journal:  Drug Alcohol Depend       Date:  2008-05-27       Impact factor: 4.492

Review 4.  Alpha₂-adrenergic agonists for the management of opioid withdrawal.

Authors:  Linda Gowing; Michael Farrell; Robert Ali; Jason M White
Journal:  Cochrane Database Syst Rev       Date:  2016-05-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.